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Background/Aims: Peripheral arterial vasodilation
may be the key factor in the sodium and water reten-
tion of cirrhosis. The mechanism responsible for this
vasodilation remains to be fully elucidated. Adreno-
medullin is a novel peptide, highly expressed in cardio-
vascular tissues, with potent and long-lasting vasodil-
ating activity.
Methods: The possible implication of adrenomedullin
in the hemodynamic changes of cirrhosis has been in-
vestigated. We measured the plasma concentration of
adrenomedullin in 20 cirrhotic patients and 11 healthy
subjects. In addition, systemic, portal and renal hemo-
dynamics, hormonal factors and renal function par-
ameters were evaluated in the same patients.
Results: Circulating adrenomedullin was significantly
higher in the group of patients with cirrhosis (72.1;
46–100 vs 21.6; 11–34 fmol/dl, respectively; p°0.02)
and was directly correlated with the Pugh score (r:
C and portal hypertension are associatedwith high cardiac output and low systemic vascu-
lar resistance. These changes are more pronounced as
liver disease progresses and may be secondary to pe-
ripheral vasodilatation, which in turn has been pro-
posed as a key factor in initiating the sodium and water
retention of cirrhosis (1).
The pathogenesis of the circulatory changes ob-
served in cirrhotic patients has not been fully clarified,
and while overproduction of nitric oxide (NO) may
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0.6; p: 0.01), inversely correlated with the creatinine
clearance (r: »0.6; p°0.01) and tended to inversely
correlate with systemic vascular resistance index (r:
»0.46; p: 0.07). There were no portal-peripheral dif-
ferences in adrenomedullin levels. Transjugular in-
trahepatic portosystemic shunt insertion did not in-
duce changes in the peripheral concentration of adre-
nomedullin, but baseline values of this hormone pre-
dicted the degree of hyperdynamic circulation after
TIPS.
Conclusions: Circulating adrenomedullin is increased
in cirrhosis. These levels increase with the severity of
the disease, especially in patients with hepatorenal
syndrome. This peptide may contribute to vasodilation
of cirrhosis.
Key words: Adrenomedullin; Cirrhosis; Peripheral
vasodilation.
play a role (2–6), the predominant isoform of NO-syn-
thase (constitutive or inducible) remains unsettled. Re-
cently, a major role of the inducible calcium and cal-
modulin-independent isoform has been disputed (7–
15). Conversely, the increased NO-synthase activity in
cirrhotic rats seems to depend on the constitutive iso-
form (15). It has also been suggested that endothelial
constitutive NO-synthase (e-NOS) up-regulation may
be a consequence of pulsatile blood flow and shear
stress on wall vessels (16). However, long-term inhi-
bition of NO synthesis reversed the hyperdynamic cir-
culation of cirrhotic rats (14). Circulating levels of po-
tent vasodilating peptides that could contribute to the
up-regulation of e-NOS, such as substance-P and
CGRP are found to be elevated in cirrhotic patients
(17,18). Hence, the study of new endothelium-depend-
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ent vasodilating peptides and their relationship to the
extent of the hemodynamic disturbance of cirrhosis is
warranted.
Adrenomedullin is a novel 52 amino acid peptide
which shares slight homology with CGRP (19), orig-
inally isolated from human pheochromocytomas (20),
and may be involved in the regulation of blood press-
ure. Endothelial cells are thought to be an important
source of adrenomedullin (21). Most immunoreactive
adrenomedullin is also expressed in adrenal gland,
lung, cardiac atria and splanchnic organs (22). Adre-
nomedullin is capable of eliciting potent and long-last-
ing forearm vasodilation in human volunteers at rela-
tively low doses (23) and shows functional antagonism
to endothelin-I as a part of a complex regulatory sys-
tem of the vascular tone (24). It has been shown that
vasodilation caused by adrenomedullin but not by
CGRP depends upon NO endothelial release (25). In
addition, it is believed that adrenomedullin causes
vasodilation by increasing the intracellular cyclic-AMP
(19). Although increased plasma levels of adrenomed-
ullin in cirrhosis have recently been reported (26–28),
little is known about the relationship between plasma
adrenomedullin values and the extent of the circul-
atory disturbance in this condition. This work was
undertaken to determine plasma adrenomedullin levels
in relation to the degree of hemodynamic disturbance
and renal and hepatic function changes occurring in
patients with cirrhosis.
Patients and Methods
Our study included 11 healthy subjects (control group)
and 20 patients with histologically proven liver cir-
rhosis. Adrenomedullin was also determined in ten pa-
tients with chronic renal failure before and immedi-
ately after undergoing hemodialysis. Five of these pa-
tients had high blood pressure.
Patients with cirrhosis with at least one of the fol-
lowing criteria were excluded from the present study:
active gastrointestinal bleeding or recent bleeding and
unstable condition, severe hepatic encephalopathy that
precluded cooperation, cardiopulmonary diseases, dia-
betes mellitus requiring insulin, arterial hypertension,
bacterial infection, portal vein thrombosis and intake
of propranolol or any other cardioactive drug, as well
as diuretics or non-steroidal anti-inflammatory drugs
(NSAIDs) at least 10 days prior to admission. Cir-
rhosis was of alcoholic origin in all cases, except in
three patients with chronic infection due to hepatitis C
virus.
Our series of patients included four patients of Child
class A, four of Child B and 12 of Child C (29). Thir-
teen of the patients were males and seven females, and
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age was 55”8 years. Two of the patients manifested
hepatorenal syndrome as defined by the diagnostic cri-
teria recently set by the International Ascites Club
(30). Six patients required transjugular intrahepatic
portosystemic shunt (TIPS) insertion because of gas-
troesophageal variceal bleeding that recurred despite
standard pharmacological and endoscopic treatment
(three patients) and refractory ascites (three patients).
The second hemodynamic study was performed 1
month after TIPS insertion in five patients and 6
months after TIPS in one. The second sampling for
adrenomedullin determination was done at the same
time as the second hemodynamic study.
The control group consisted of seven males and
three females (age 49”4 years). The study also in-
cluded ten sex- and age-matched patients with chronic
renal failure. The protocol was approved by the Ethics
Committee at the Hospital Xeral de Vigo and the Of-
fice of Human Subjects Research at the National
Health Institutes in Bethesda, MD, USA. Written in-
formation was given to all patients and written in-
formed consent was obtained from each participating
patient.
Both controls and patients were placed on rest and
on a 40–60 mmol/day sodium diet for 5 days. Di-
uretics, beta-blockers and other cardioactive drugs
were withheld during this period of the study.
Protocol
The day after admission, samples of urine and venous
blood were obtained for routine analytical studies. An
electrocardiogram, chest film and abdominal ultra-
sonography were also performed. On the fourth day a
blood sample was drawn and a 24-h urine sample was
collected for renal function studies. On the fifth day
the central venous pressure was recorded, as well as
the heart rate and blood pressure. At 9.00 a.m. blood
samples were drawn for plasma renin activity (PRA)
and plasma aldosterone concentration (PAC) determi-
nation. Plasma samples for adrenomedullin determi-
nation were immediately centrifuged at 4¾C and the
supernatant was stored at »70¾C until determination.
PRA was determined by radioimmunoassay for Angio-
tensin I (Angiotensin radioimmunoassay test, Sorin Bi-
omedica, 13040 Vercelli, Italy) and PAC by direct
radioimmunoassay (Aldosterone II RIA diagnostic kit,
Abbott Laboratories, Germany). Plasma adrenomed-
ullin was determined in both peripheral venous blood
and portal vein blood samples in five patients at the
time of TIPS placement.
Radioimmunoassay (RIA) of adrenomedullin
Serum samples (1.0 ml) were mixed with an equal vol-
ume of 0.1% alkaline-hydrolysed-treated casein (31) in
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phosphate-buffered saline (PBS), and extracted
through C-18 Sep-Pak 400 mg cartridges (Waters
Corp, Mildford, MA, USA). The proteins were eluted
with 80% isopropanol and the recovered volume was
freeze dried to eliminate the organic solvent. Extracts
were reconstituted in 400 ml RIA assay buffer (10 M
phosphate, 50 mM ethylenediamine tetraacetate, 135
mM NaCl, 0.05% Triton X-100, 0.1% Tween 20, 1%
bovine serum albumin (BSA), 0.1% alkaline-hydro-
lysed-treated casein, 20 mg/l phenol red, pH 7.5), spun
at 14 000 rpm for 10 min at 4¾C to remove any solid
matter, and three 100-ml aliquots from each sample
were separated for analysis. The RIA was performed
using the Phoenix human adrenomedullin RIA kit and
following the manufacturer¿s instructions. Briefly, 100
ml of anti-adrenomedullin antibody and 125I-adreno-
medullin (15 000 cpm) were added to each sample and
the mixture was incubated for 16 h at 4¾C. After centri-
fugation at 3750 rpm for 30 min at 4¾C, the super-
natant was discarded, separation of bound and free
tracer was accomplished using a 1:200 dilution of goat
anti-rabbit IgG in a 6% PEG 8000 matrix, and the
radioactivity in the pellets was measured in a 1277
Gammamaster instrument (Wallac, Gaithersburg, MD,
USA). The radioactive counts were compared to a
standard curve, and the concentration of adrenomed-
ullin was calculated by linear regression. Recovery in
the assay averaged 66% and the variation between as-
says was less than 10%. The displacement of tracer ob-
tained by increasing volumes of serum extracts was
parallel with that observed with the standard curve.
The coefficient of variation intra-assay was 6% and the
detection limit was 1.6 fmol/dl. The r-square for lin-
earity was 0.990, the slope »2.6 and the B50 11.8 fmol/
dl.
Hemodynamic calculations
In the fasting patients, on the fifth day, at 9.00 a.m. a
pulsed Doppler echocardiographer was used (Vingmed
700 CMF, Horten, Norway, with a 3.5 MHz trans-
ducer) to determine the cardiac output from a Fourier-
transformed left ventricle outflow curve, through an
apical window, after bidimensional images were ob-
tained. We found a fair correlation between the values
of stroke volume and cardiac output as estimated by
radionuclide ventriculography and the echo-Doppler
method (n: 16: r: 0.8: p: 0.02. Ferna´ndez-Rodriguez
CM, Penas J, Guitia´n R. Unpublished observation). To
avoid interobserver variation, this determination was
performed by the same observer throughout the study
(J.P.). The coefficient of intra-observer variation was
less than 5%. In addition, the results of this non-invas-
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ive technique have been shown to correlate with those
obtained by the thermodilution method (32–34). A
complete systemic hemodynamic study was performed
on five healthy subjects. Since the apical window was
considered inappropriate in three patients, complete
systemic hemodynamic data were available from 17 pa-
tients. In six patients the hemodynamic study and hor-
monal determinations were repeated after TIPS inser-
tion. The patency of TIPS was verified by Doppler
sonography. The cardiac and systemic vascular resist-
ance indexes were corrected for the body surface ac-
cording to the ideal body area in patients with ascites
and/or edema (35):
IBW‰(H»100) » (H»150)/4
where H stands for height.
Statistical analysis
Results are presented as means and standard deviation,
medians and ranges. The unpaired two-tailed t-test was
used for comparison between means of normally dis-
tributed data. The Wilcoxon test and the Mann-Whit-
ney U test were performed for nonparametric paired
and unpaired comparison between two groups, respec-
tively. Linear coefficients of correlation were also used
in the analysis of the results. P-values less than 0.05
were considered significant. Since the distribution of
the values of plasma adrenomedullin is not normal and
the variances of data are not homogeneous (homoced-
TABLE 1
Hemodynamic, hormonal and renal function parameters in healthy
subjects and cirrhotic patients
Control Cirrhotic p
Nap (mEq/l) 140”1.4 136”1.5 N.S.
Ccr (ml/min) 128”17 71”8 °0.01
UNaV (mEq/24 h) 127”23.6 36”7.7 °0.01
MAP (mmHg) 80”4.1 82.7”9.1 N.S.
CVP (mmHg) 3”0.4 3.6”0.3 N.S.
SVRI 2105”170 1815”100 °0.05
(dyn ` s»1 ` cm»5 ` m»2)
CI (l ` min»1 ` m»2) 2.7”0.19 3.8”0.2 °0.05
HVPG (mmHg) 18.3”4.9
PRA (ng ` ml»1 ` h»1) 0.6”0.26 9.3”3 °0.05
PAC (ng/ml) 126”36 1398”739 °0.05
Albumin (g/dl) 3.9”0.1 2.9”0.23 °0.01
Bilirubin (mg/dl) 0.925”0.25 3.5”0.1 °0.05
Prothombin index (%) 95”3.3 59”3.7 °0.01
Data as mean”SEM.
Nap: Plasma sodium; Ccr: Creatinine clearance (corrected for body
surface area and expressed per 1.73 m2); UNaV: Urinary excretion of
sodium; MAP: Mean arterial pressure; CVP: Central venous pressure;
CI: Cardiac index; SVRI: Systemic vascular resistance index; HVPG:
Hepatic venous pressure gradient; PRA: Plasma renin activity; PAC:
Plasma aldosterone concentration. N.S.: Non-significant differences.
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astics), the Spearman rank correlation was used for the
regression analysis.
Results
Values of hepatic, renal function, hormonal and hemo-
dynamic parameters are summarized in Table 1. The
plasma values of adrenomedullin in the group of pa-
tients were significantly higher than in the control
group (median: 58.5 fmol/ml; range 23 to 205 fmol/ml
vs 21.6 fmol/ml; range 11 to 34 fmol/ml, Fig. 1).
Patients with chronic renal failure showed higher ad-
renomedullin levels than subjects in the control group
(median: 72.1; range 46.8–100 vs 21.6 range 11–34
fmol/ml respectively; p°0.02). In addition, adrenomed-
Fig. 1. Individual values of plasma adrenomedullin in the
group of patients with cirrhosis and the control (median:
58.48; range 23.2 to 205.2 fmol/ml vs 24.1; range 11 to 34
fmol/ml, respectively). Boxes represent median values and
the interquartile ranges and the closed circles those patients
with hepatorenal syndrome. (Non-parametric Mann-Whit-
ney U test.)
Fig. 2. Plasma levels of AM in patients with chronic renal
failure prior to and after undergoing hemodialysis. Horizon-
tal lines represent the median values (72.1 vs 52 fmol/ml,
respectively). (Non-parametric Wilcoxon test.)
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ullin concentrations dropped in these patients after un-
dergoing hemodialysis (median 72.1; 46.8–100.8 vs 52;
34.4–96.6, fmol/ml, respectively; Fig. 2). Consistent
with these findings, the highest values were found in
patients with hepatorenal syndrome (closed circles,
Fig. 1). There were no differences in plasma adrenome-
dullin between renal patients with or without arterial
hypertension.
In the cirrhotic patients, no correlation was found
between adrenomedullin levels and the mean arterial
pressure nor between adrenomedullin values and the
hepatic venous gradient pressure. There was no corre-
lation between adrenomedullin levels and plasma renin
activity nor with plasma aldosterone concentration.
Plasma levels of this peptide correlated inversely with
creatinine clearance (Fig. 3) and correlated directly
with the Pugh score (r: 0.6; p: 0.01). Adrenomedullin
values tended to inversely correlate with systemic vas-
cular resistance index, although without reaching stat-
istical significance (r: »0.46; p:0.07).
Six patients were treated with TIPS. In these pa-
tients, the cardiac index increased after the procedure
(3.75; 2.3–4.2 vs 4.2; 2.2–6.7 l ` min»1 ` m»2, respec-
tively; p°0.05). However, plasma adrenomedullin con-
centration was similar before and after TIPS (median:
38.8; range 10.1–205.2 vs 38, range 35.4–49.8 fmol/ml,
respectively; p: 0.27). We also found that the concen-
tration of adrenomedullin in the portal vein was simi-
lar to that found in the peripheral circulation (54.1”19
vs. 53.41”46; n: 5; N.S.). Interestingly, the baseline ad-
renomedullin levels predicted the intensity of hyperdy-
namic circulation which developed in the cirrhotic pa-
tients after TIPS insertion, since the baseline plasma
Fig. 3. Inverse correlation between the plasma AM concen-
tration and the creatinine clearance in the group of patients.
(Non-parametric Spearman rank correlation.)
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Fig. 4. A. Correlation between the plasma AM concen-
tration and the cardiac index (CI) after transjugular in-
trahepatic portosystemic shunt (TIPS) insertion patients
with cirrhosis. (Non-parametric Spearman rank corre-
lation.). B. Inverse correlation between the plasma AM
levels and the systemic vascular resistance index after
TIPS. (Non-parametric Spearman rank correlation.)
adrenomedullin levels directly correlated with the car-
diac index after TIPS (Fig. 4A), and there was a nearly
significant inverse correlation with the systemic vascu-
lar resistance index (SVRI) after TIPS placement (Fig.
4B).
Discussion
Our findings confirm previous observations on the
presence of hyperdynamic circulation in liver cirrhosis
(36–38), and show increased plasma levels of adreno-
medullin-like immunoreactivity in patients with cir-
rhosis as compared with healthy controls. Cheung &
Leung reported increased adrenomedullin levels in dif-
ferent conditions including liver cirrhosis (27). The ab-
solute values of plasma adrenomedullin reported by
these authors were different from the values obtained
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in the present study. These differences may be due to
the different radioimmunoassay and different anti-
bodies used. The relative changes in adrenomedullin,
observed in patients with cirrhosis, are similar in both
studies.
In our patients the plasma levels of this vasodilator
correlated directly with the Pugh score and inversely
with creatinine clearance. It can be reasoned that re-
duced hepatic or renal clearance, or both, could ac-
count for our results. Nevertheless, our results on the
portal-systemic gradient indicate that there is no net
hepatic clearance of adrenomedullin in patients with
cirrhosis. We did not measure the renal arteriovenous
concentration of adrenomedullin. However, the
marked reduction in plasma adrenomedullin concen-
tration after hemodialysis in patients with chronic re-
nal failure suggests that a defective renal clearance
might contribute to the increased levels observed in
those patients with chronic renal insufficiency or with
hepatorenal syndrome. An increased adrenomedullin
production to counterbalance plasma volume overload
might be an additional mechanism accounting for in-
creased adrenomedullin plasma concentration in renal
patients (39).
An increased adrenomedullin production in cir-
rhosis may account for the elevation of plasma adreno-
medullin levels in our patients. Substances such as tu-
mor necrosis factor-a (TNF-a) or endotoxin are re-
ported to be increased in cirrhosis (40–43) and it has
been shown that TNF-a markedly stimulates the pro-
duction and secretion of adrenomedullin by vascular
smooth muscle cells (VSMCs) (44). Therefore, in-
creased adrenomedullin activating substances such as
mild endotoxemia and/or increased circulating levels of
TNF-a, as observed in advanced liver diseases (40–43),
could enhance adrenomedullin synthesis, thus increas-
ing adrenomedullin-mediated NO production. In ad-
dition to these compounds, several vasoactive com-
pounds such as substance-P, endothelin-I and adrena-
lin, all of which have been found to be increased in the
peripheral circulation of cirrhotic patients (17,45,46)
are capable of stimulating adrenomedullin production
by VSMCs (47).
Although the correlation did not reach conventional
statistical significance, adrenomedullin levels tended to
correlate inversely with the systemic vascular resistance
index, which suggests that this peptide might partici-
pate in the hemodynamic disturbance of cirrhosis. In
our study, the SVRI of those patients with advanced
disease may have been overestimated, as it was calcu-
lated from body surface area according to the Lorentz
formula. It has been suggested that this formula may
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overestimate weight in wasted patients with ascites and
edema (35).
It is interesting that plasma values of adrenomedul-
lin predicted the intensity of further vasodilatation in
patients after TIPS placement. It has been suggested
that activation of endogenous vasoconstrictor forces
may offset or attenuate the effect of vasodilating sub-
stances (17). After TIPS insertion, a partial deacti-
vation of the vasoconstrictor forces occurs (48), be-
cause of either increased replenishment of the central
vascular compartment or alleviation of the intrasinuso-
idal pressure. Therefore, TIPS may render vasodilatory
activity unopposed. Thus, the higher the plasma adre-
nomedullin levels pre-TIPS, the more intense post-
TIPS vasodilation would be. On the other hand, the
lack of correlation between the adrenomedullin con-
centration and the hepatic venous pressure gradient
suggests that intrasinusoidal hypertension does not
play a significant role in the elevation of plasma adre-
nomedullin. In fact, adrenomedullin levels did not
change after reduction of sinusoidal hypertension. The
lack of effect of TIPS on plasma levels of vasodilating
peptides has also been shown in the case of substance-
P (17).
In addition to adrenomedullin, other humoral fac-
tors causing endothelial-dependent vasorelaxation
have been found to be increased in cirrhosis (17,18).
Whether or not these compounds might have a syner-
gistic action in the up-regulation of e-NOS, observed
in cirrhotic rats (49) requires further research.
In summary, circulating adrenomedullin is increased
in cirrhosis, especially in patients with poor hepatic
and renal function and more severe peripheral arterial
vasodilation. Plasma levels of adrenomedullin seem to
accurately predict the development of hyperkinetic cir-
culation after the placement of TIPS. It is concluded
that this potent vasodilator may be involved in the pe-
ripheral vasodilation of cirrhosis.
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